An introduction from  139
our management
- Chairman’s Statement Economics
- Letter from the CEO
01
Proportion of spending on local suppliers 
Chiesi at a Glance
02 In 2019, in Italy, Chiesi sourced 46.3% of its goods from national suppliers, leaving 
Positive Impacts  s
a significant percentage for local suppliers, a positive impact on the communities  e
and Challenges x
e
- Products and Patients in which we operate. In other significant locations of the Group, around 75.6% of  nn
- Processes A
Chiesi supplies were purchased locally.
- Global Value Chain
- Corporate Citizenship
03
Spending on local
Chiesi’s contribution 
suppliers - %
to the UN Sustainable 
Country 
Development Goals
2019* 2018**
04
Annexes Australia (Emerge Health Pty) 90 N/A
- Impact Report
- Data, Methodology  Austria (Chiesi Pharmaceuticals GMBH) 47 45
   and GRI Content Index
Bulgaria (Chiesi Bulgaria ltd) 95 94.2
Czech Republic (Chiesi cz SRO) 83 87.1
Hungary (Chiesi Hungary kft) 14 24
Romania (Chiesi Romania srl) 91 88.6
Slovenia (Chiesi Slovenija d.o.o.) 97 89
Slovakia (Chiesi Slovakia SRO) 91 88.9
Belgium (Chiesi SA) 95 97.6
Brazil (Chiesi Farmaceutica Ltda.) 84 63
China (Chiesi Pharmaceuticals Shanghai Co. Ltd) 99 98
Denmark (Zymenex Holding A/S) 98 Not available
France (Chiesi SAS) 62 77.7
France (Nh.Co) 78 Not available
Germany (Chiesi gmbh) 95 98
Greece (Chiesi Hellas Pharmaceuticals SA) 94 94.7
Italy (Chiesi Farmaceutici) 46 55.8
Italy (Marco Antonetto) 94 Not available
Mexico (Chiesi Mexico S.A. DE C.V.) 97 Not available
Netherlands (Chiesi Pharmaceuticals B.V.) 95 93.8
Pakistan (Chiesi Pharmaceuticals (Pvt) Ltd.) 97 Not available
Poland (Chiesi Poland SP Z.O.O.) 88 97.1
Russia (LLC Chiesi Pharmaceuticals) 86 Not available
Spain (Chiesi España S.A.) 83 86.5
Sweden (Chiesi Pharma AB) 83 Not available
Switzerland (Chiesi S.A.) 100 N/A